PH12018500827A1 - 6-[5-amino-6-(2-ethoxyethoxy)-imidazo[4,5-b]pyridin-3-yl]-nicotinonitrile derivatives and their use as irak inhibitors - Google Patents

6-[5-amino-6-(2-ethoxyethoxy)-imidazo[4,5-b]pyridin-3-yl]-nicotinonitrile derivatives and their use as irak inhibitors

Info

Publication number
PH12018500827A1
PH12018500827A1 PH12018500827A PH12018500827A PH12018500827A1 PH 12018500827 A1 PH12018500827 A1 PH 12018500827A1 PH 12018500827 A PH12018500827 A PH 12018500827A PH 12018500827 A PH12018500827 A PH 12018500827A PH 12018500827 A1 PH12018500827 A1 PH 12018500827A1
Authority
PH
Philippines
Prior art keywords
ethoxyethoxy
imidazo
pyridin
amino
irak inhibitors
Prior art date
Application number
PH12018500827A
Other languages
English (en)
Inventor
Reginald Christophe Xavier Brys
Raphael Jean Joel Geney
Agnes Marie Joncour
Julien Georges Pierre-Olivier Doyon
Frederic Gilbert Labeguere
Jean-Michel Lefrancois
Oscar Mammoliti
Benoit Antoine Schmitt
Der Plas Steven Emiel Van
Christel Jeanne Marie Menet
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Nv filed Critical Galapagos Nv
Publication of PH12018500827A1 publication Critical patent/PH12018500827A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PH12018500827A 2015-10-19 2018-04-17 6-[5-amino-6-(2-ethoxyethoxy)-imidazo[4,5-b]pyridin-3-yl]-nicotinonitrile derivatives and their use as irak inhibitors PH12018500827A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1518456.7A GB201518456D0 (en) 2015-10-19 2015-10-19 Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory, autoimmune and/or proliferative diseases
PCT/EP2016/074662 WO2017067848A1 (en) 2015-10-19 2016-10-14 6-[5-amino-6-(2-ethoxyethoxy)-imidazo[4,5-b]pyridin-3-yl]-nicotinonitrile derivatives and their use as irak inhibitors

Publications (1)

Publication Number Publication Date
PH12018500827A1 true PH12018500827A1 (en) 2018-10-29

Family

ID=55131239

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12018500827A PH12018500827A1 (en) 2015-10-19 2018-04-17 6-[5-amino-6-(2-ethoxyethoxy)-imidazo[4,5-b]pyridin-3-yl]-nicotinonitrile derivatives and their use as irak inhibitors

Country Status (18)

Country Link
US (1) US10508111B2 (enExample)
EP (1) EP3365341B1 (enExample)
JP (1) JP2018530617A (enExample)
KR (1) KR20180064528A (enExample)
CN (1) CN108137584A (enExample)
AR (1) AR106384A1 (enExample)
AU (1) AU2016343225A1 (enExample)
BR (1) BR112018007392A2 (enExample)
CA (1) CA3002255A1 (enExample)
CO (1) CO2018004765A2 (enExample)
GB (1) GB201518456D0 (enExample)
IL (1) IL258707A (enExample)
MX (1) MX2018004517A (enExample)
PH (1) PH12018500827A1 (enExample)
RU (1) RU2018117499A (enExample)
SG (1) SG11201803095UA (enExample)
TW (1) TW201718582A (enExample)
WO (1) WO2017067848A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20180011A1 (ar) 2017-02-16 2019-01-30 Gilead Sciences Inc مشتقات بيرولو [1، 2-b]بيريدازين
GB201702603D0 (en) * 2017-02-17 2017-04-05 Galápagos Nv Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders
WO2019111218A1 (en) 2017-12-08 2019-06-13 Cadila Healthcare Limited Novel heterocyclic compounds as irak4 inhibitors
TWI842978B (zh) 2018-07-13 2024-05-21 美商基利科學股份有限公司 衍生物
GB201904373D0 (en) * 2019-03-29 2019-05-15 Galapagos Nv Novel compounds and pharamaceutical compositions thereof for the treatment of inflammatory disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY28506A1 (es) * 2003-09-12 2005-04-29 Basf Ag 6-halógeno-(1,2,4)triazolo(1,5-a)pirimidinas para combatir plagas animales.
ES2389203T3 (es) * 2004-01-12 2012-10-24 Ym Biosciences Australia Pty Ltd Inhibidores de quinasa selectivos
CN103476767B (zh) * 2011-02-09 2015-06-10 弗·哈夫曼-拉罗切有限公司 作为pi3激酶抑制剂的杂环化合物
BR112016006319A2 (pt) * 2013-09-27 2017-08-01 Nimbus Iris Inc inibidores de irak e usos dos mesmos
UY35935A (es) * 2014-01-03 2015-06-30 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Compuestos de nicotinamida sustituida con heteroarilo como inhibidores de quinasa y moduladores de irak-4

Also Published As

Publication number Publication date
BR112018007392A2 (pt) 2018-10-16
US10508111B2 (en) 2019-12-17
TW201718582A (zh) 2017-06-01
MX2018004517A (es) 2018-06-27
RU2018117499A (ru) 2019-11-21
SG11201803095UA (en) 2018-05-30
WO2017067848A1 (en) 2017-04-27
EP3365341B1 (en) 2020-05-13
IL258707A (en) 2018-06-28
US20180305351A1 (en) 2018-10-25
CA3002255A1 (en) 2017-04-27
GB201518456D0 (en) 2015-12-02
CN108137584A (zh) 2018-06-08
CO2018004765A2 (es) 2018-07-19
RU2018117499A3 (enExample) 2020-01-24
AU2016343225A1 (en) 2018-05-10
KR20180064528A (ko) 2018-06-14
JP2018530617A (ja) 2018-10-18
AR106384A1 (es) 2018-01-10
EP3365341A1 (en) 2018-08-29

Similar Documents

Publication Publication Date Title
MX2021013110A (es) Compuestos heterociclicos como inhibidores de la cinasa ret.
PH12018502125A1 (en) Bipyrazole derivatives as jak inhibitors
PH12017502050B1 (en) Naphthyridine compounds as jak kinase inhibitors
PH12017501921A1 (en) Novel compounds
MX370390B (es) Compuesto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]pirazolo[1, 5-a]pirimidin-3-carboxamida util como inhibidor de cinasa de ataxia telangiectasia mutada (atm) y rad3 relacionados (atr), su preparacion, diferentes formas solidas y sus derivados radiomarcados.
JOP20190143A1 (ar) مثبطات جزيئات صغيرة من عائلة jak لإنزيمات الكيناز
NZ749911A (en) Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
PH12018500827A1 (en) 6-[5-amino-6-(2-ethoxyethoxy)-imidazo[4,5-b]pyridin-3-yl]-nicotinonitrile derivatives and their use as irak inhibitors
MX2015014234A (es) Derivados 2-aminopirido-[4,3-d]pirimidin-5-ona y su uso como inhibidores de wee-1.
PH12015502248A1 (en) 6-(5-hydroxy-1h-pyrazol-1-yl)nicotinamide derivatives and their use as phd inhibitors
ZA202105353B (en) Pyrazolopyridines and triazolopyridines as a2a / a2b inhibitors
WO2016010869A3 (en) FUSED QUINOLINE COMPUNDS AS PI3K, mTOR INHIBITORS
PH12017500007A1 (en) Quinolizinone derivatives as p13k inhibitors
EA201991355A1 (ru) Производные имидазо[1,5-а]пиразина в качестве ингибиторов pi3kдельта
HK1252245A1 (zh) 用於治疗癌症的核苷酸
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
EA032654B9 (ru) [1,2,4]ТРИАЗОЛО[4,3-b]ПИРИДАЗИНЫ ДЛЯ ПРИМЕНЕНИЯ В ЛЕЧЕНИИ ПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ
NZ740119A (en) Cyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide
PH12015502746A1 (en) Prodrug derivatives of substituted triazolopyridines
MX2018004879A (es) Nuevos derivados de piridona y su uso como inhibidores de quinasas.
PH12016500173A1 (en) Derivatives of 1 h-pyrazolo[3,4-b]pyridine and pharmaceutical compositions thereof for the treatment of proliferative disorders
MY193381A (en) Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
HK1228399A1 (en) Protein kinase inhibitors
MY192305A (en) Bipyrazole derivatives as jak inhibitors